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Abstract 
Introduction. Cyanide is a rapidly acting poison existing in various forms. It is a toxicant in 
fire smoke and a substance used by some professional groups. Objectives. This article 
reviews the multiple routes and possible sources of acute cyanide poisoning and their 
association with certain occupations. Pathophysiology. Cyanide can kill within seconds or 
minutes to hours of exposure, through the inhibition of the mitochondrial cytochrome oxidase 
a3, causing intracellular hypoxia. Detoxification. Cyanide is mainly detoxified in the liver by 
the enzyme rhodanese to the less toxic thiocyanate. Other route is reaction with 
hydroxocobalamin to form cyanocobalamin excreted in urine. Inhalation. Modern structural 
fires can generate toxic levels of hydrogen cyanide, making the inhalation of smoke in a 
closed-space fire the most common cause of cyanide poisoning in industrialised countries. 
Inhalation of this toxic is also possible in occupational or industrial accidents. Ingestion. 
Suicide attempts are the most common reason for cyanide ingestion. There is a strong 
association between suicide by ingestion of cyanide and certain professional groups, namely 
jewellers, chemists or miners. Ingestion of this poison can also occur as an accident in some 
occupations. Nitriles are cyanogenic compounds with a delayed onset of cyanide toxicity, 
causing poisoning most often due to suicide attempts or accidental ingestion by young 
children. There are cyanogenic glycosides that can cause toxicity, normally occurring as an 
accidental poisoning. Dermal contact and parenteral administration. Dermal exposure and 
subcutaneous injection of cyanide are rare causes of poisoning. Sodium nitroprusside is an 
inorganic hypotensive agent that can be an iatrogenic source of cyanide. Clinical 
manifestations and laboratory findings. Early symptoms of poisoning represent the reflexive 
attempts of the organism systems to overcome hypoxia and late symptoms reflect these 
systems depression. Patients with acute cyanide intoxication have markedly elevated plasma 
lactate concentration, high anion gap metabolic acidosis and reduced arteriovenous oxygen 
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saturation difference. Diagnosis. The diagnosis is generally based on index of suspicion, 
clinical presentation and laboratory findings, since there is no blood cyanide test available on 
an emergent basis. Treatment. Management of patients with acute cyanide poisoning requires 
decontamination, supportive care and the early administration of an antidote. From the 
antidotes available, hydroxocobalamin seems to have the best risk-benefit profile and has 
been recommended as an antidote of first choice. Follow-up. Most patients who survive 
cyanide intoxication will be free of complications. Nonetheless, some may develop 
parkinsonism or other symptoms. Conclusion. Acute cyanide poisoning can occur through 
several routes. Smoke inhalation is the most common in industrialised countries. Many 
professional groups have prompt access to this toxic, so the possibility of poisoning should be 
strongly considered in those workers when they present a clinical picture and laboratory 
findings suggestive of cyanide. An antidote, preferably hydroxocobalamin, should be 
administered.   
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Resumo 
Introdução. O cianeto é um veneno de rápida ação existente em várias formas. Encontra-se 
presente no fumo resultante de incêndios, assim como é uma substância usada em algumas 
profissões. Objetivos. Este artigo faz uma revisão das múltiplas vias e possíveis fontes da 
intoxicação aguda com cianeto, assim como a sua associação com certas ocupações. 
Patofisiologia. O cianeto é letal em poucos segundos ou minutos a horas após a exposição, 
através da inibição da enzima citocromo oxidase a3 mitocondrial, causando hipóxia 
intracelular. Destoxificação. O cianeto é sobretudo destoxificado no fígado pela ação da 
enzima rodanase, com a sua conversão no composto menos tóxico tiocianato. Outra via 
existente é a reação com a hidroxocobalamina para formar cianocobalamina, excretada na 
urina. Inalação. Os incêndios em estruturas modernas podem produzir níveis tóxicos de ácido 
cianídrico, tornando a inalação de fumo num incêndio num espaço fechado a causa mais 
comum de intoxicação por cianeto nos países industrializados. A inalação deste tóxico 
também pode ocorrer em acidentes ocupacionais ou industriais. Ingestão. As tentativas de 
suicídio são o motivo mais comum para a ingestão de cianeto. Existe uma forte associação 
entre o suicídio pela ingestão deste tóxico e certos grupos profissionais, nomeadamente 
joalheiros, químicos ou mineiros. A ingestão de cianeto também pode ocorrer por acidente 
em algumas ocupações. Os nitrilos são compostos cianogênicos que provocam toxicidade 
pelo cianeto de início tardio, causando envenenamento normalmente devido a tentativas de 
suicídio ou ingestão acidental por crianças pequenas. Existem glicosídeos cianogênicos que 
podem causar toxicidade, normalmente ocorrendo de forma acidental. Contacto dérmico e 
administração parentérica. A exposição dérmica e injeção subcutânea de cianeto são causas 
raras de envenenamento. O nitroprussiato de sódio é um composto inorgânico hipotensor que 
pode ser uma fonte iatrogénica de cianeto. Manifestações clínicas e achados laboratoriais. 
Os sintomas precoces representam a tentativa inicial do organismo em superar a hipóxia e os 
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sintomas tardios refletem a depressão sistémica que acaba por ocorrer. Os pacientes com 
intoxicação aguda apresentam uma concentração plasmática de lactato acentuadamente 
elevada, uma acidose metabólica com aumento do “gap” aniónico e uma diferença artério-
venosa de oxigénio reduzida. Diagnóstico. O diagnóstico geralmente baseia-se no índice de 
suspeição, apresentação clínica e achados laboratoriais, dado que não existe nenhuma análise 
sanguínea que detete o cianeto atempadamente num contexto de emergência. Tratamento. O 
tratamento da intoxicação aguda com cianeto passa pela descontaminação, cuidados de 
suporte e a administração precoce de um antídoto. Dos antídotos disponíveis, a 
hidroxocobalamina parece apresentar o melhor perfil risco-benefício e tem sido recomendada 
como o antídoto de primeira escolha. Seguimento. A maioria dos doentes que sobrevive ao 
envenenamento com cianeto não fica com complicações da intoxicação. No entanto, alguns 
podem desenvolver parkinsonismo ou outros sintomas. Conclusão. A intoxicação aguda por 
cianeto pode ocorrer através de diversas vias. A inalação de fumo é a mais comum nos países 
industrializados. Várias profissões têm acesso facilitado a esta substância, de tal forma que a 
possibilidade de envenenamento deve ser fortemente considerada nesses trabalhadores 
quando apresentarem um quadro clínico e achados laboratoriais sugestivos de cianeto. Um 
antídoto, preferencialmente a hidroxocobalamina, deve ser administrado.           
 
Palavras-chave Envenenamento; Joalheiro; Hidroxocobalamina; Antídoto 
 
Contagem de palavras do resumo: 505 
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Introduction 
Cyanide is considered one of the most rapidly acting and deadly poisons (1). It can kill within 
seconds or minutes to hours of exposure, depending on the route and length of exposure, the 
form of cyanide, as well as the amount received (1, 2). Cyanide exists in gas, liquid and solid 
forms and has many natural, industrial, environmental and even iatrogenic sources (1, 3). 
Therefore, it is not surprising that it can cause human toxicity via multiples routes including 
inhalation, ingestion, dermal or conjunctival contact and parenteral administration (1). 
Although acute poisoning is infrequently, the increased understanding that cyanide can 
contribute to death of victims of smoke inhalation in enclosed space fires, the existence of 
multiple sources of cyanide, the frequent association with certain professional groups, the 
difficult in the diagnosis without an history of exposure and the availability of an antidote 
that can be used as empiric therapy in the prehospital and hospital settings make cyanide an 
agent of continued clinical interest.   
 
Objectives 
This article reviews acute cyanide poisoning with particular focus on the multiples routes of 
cyanide toxicity as well as the possible sources of cyanide and their association with some 
professional groups. 
 
Methods  
A search of published studies on cyanide poisoning was performed with PubMed (last 
accessed 27 December 2011). Search terms were “cyanide poisoning”, “cyanide exposure”, 
“cyanide intoxication”, “cyanide ingestion” and “cyanide inhalation”. The limits were articles 
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in English or in Portuguese and in humans. Studies regarding chronic intoxication were 
excluded. The search originated 1335 results. After reading the title and/or the abstract, were 
selected 230 relevant publications for further search of the full text, 106 of which were found. 
Another search using the terms “community” and “cyanide” was performed with Web of 
Knowledge, and from the 80 results only one article was selected and the abstract obtained. 
From the references of the obtained articles, two more were selected by their relevance. The 
full text was obtained for one and the abstract for the other.  
From the total of 109 articles obtained, 63 were used as references for this review. 
 
Pathophysiology of cyanide poisoning 
Cyanide poisoning can rapidly culminate in incapacitation and death because it diffuses into 
tissues and binds to target organs within seconds after exposure. Inhaled and intravenous 
exposures produce more rapid onset of symptoms than does oral ingestion. Inhalation of 
hydrogen cyanide and other cyanide gases can be rapidly lethal because of fast diffusion of 
cyanide across alveolar membranes and direct distribution to organs via the bloodstream. In 
the same way intravenous administration can be lethal within seconds because of fast and 
direct exposure of target organs to this toxic. Dermal or oral ingestion may produce a delay in 
symptoms as concentrations rise in the bloodstream (1, 4).  
The toxic action of cyanide is attributed to the cessation of aerobic cell metabolism. It inhibits 
the mitochondrial cytochrome oxidase a3, an enzyme necessary for the reduction of oxygen to 
water in the fourth complex of oxidative phosphorylation. This oxidative metabolism via the 
electron transport chain is responsible for creating large amounts of adenosine triphosphate 
(ATP) that is the primary source of cellular energy. Cyanide, which has a chemical structure 
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similar to that of oxygen, reversibly binds to the ferric iron portion of cytochrome oxidase a3, 
inhibiting the terminal enzyme in the respiratory chain and cease electron transport and 
oxidative phosphorylation. This results in a decrease of ATP production. As supplies of ATP 
become depleted and since the mitochondria is unable to extract or use the oxygen they are 
exposed to, the metabolism shifts to glycolysis through anaerobic metabolism, an inefficient 
mechanism for energy needs, that only produces a tiny amount of ATP. It also produces 
lactate. The decreased availability of ATP leads to cellular dysfunction and death (1, 4). 
 
Detoxification of cyanide 
There are natural sources of cyanide in the environment, such as cyanogenic foods. So it is 
not surprising the presence of endogenous mechanisms of cyanide detoxification in humans 
(1). About 80% of absorbed cyanide is detoxified within the liver, by the mitochondrial 
enzyme rhodanese. Rhodanese catalyzes the transfer of sulphur from a sulphate donor to 
cyanide, converting it to less toxic thiocyanate, which is then excreted in the urine. This 
pathway is rapidly and easily overwhelmed by high doses of cyanide in acute poisoning or in 
patients with impaired renal function. Other detoxification mechanisms include reaction with 
hydroxocobalamin (vitamin B12a) to form cyanocobalamin (vitamin B12), which is excreted in 
urine; and oxidation of cyanide to thiocyanate and other stable nontoxic compounds through 
enzymatic and nonenzymatic mechanisms. Small amounts of cyanide are eliminated as 
carbon dioxide by expiration, along with small amounts of hydrogen cyanide (1, 5). 
Unmetabolized cyanide has a bitter almond-like odor that is sometimes detected in cyanide 
poisoned patients. However, the ability to smell this odor seems to be genetically determined 
and about 50% of the population lacks the relevant gene (1, 2). 
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Routes of cyanide toxicity 
• Inhalation 
The most common cause of cyanide poisoning in western countries is inhalation of smoke 
from structural fires (2). The thermal breakdown of nitrogen-containing materials can 
produce toxic levels of hydrogen cyanide (6). Combustion of synthetics such as 
polyacrylonitrile, polyurethane, polyester, polyvinyl chloride, neoprene, modacrylic, 
fiberglass insulation, rubber, rayon, nylon, adhesive resins and melamine, as well as natural 
materials such as wool, silk, cotton, wood and paper, can generate high concentrations of 
hydrogen cyanide, particularly in modern structural fires, because of the abundance of these 
products (2-4, 6-8). Although carbon monoxide is the most commonly reported cause of 
smoke-inhalation mortality, Baud et al. suggest that cyanide poisoning may prevail over 
carbon monoxide poisoning as the cause of death in some fire victims (6). Thereby, acute 
cyanide poisoning should be suspected, at least as a concomitant intoxication, whenever fire 
victims have smoke inhalation in a closed-space fire, particularly if two or more of the 
following criteria are fulfilled:   
1. Soot in the mouth, nose or expectoration  
2. Signs such as altered mental status, unconsciousness, convulsions and hemodynamic 
instability  
3. Arterial blood sampling reveal metabolic acidosis with a lactate above 8 mmol/L, as 
the concentration of lactate increases proportional with the amount of cyanide 
poisoning (2, 9-11).  
Besides inhalation of fire smoke, cyanide inhalation is possible in occupational or industrial 
accidents (12-14). Global consumption of cyanide reaches 1.5 million tonnes annually. Both 
gaseous and solid forms are used in industries such as metallurgy, electroplating, metal 
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cleaning, leather tanning and photoengraving. It is also used in the gold and silver extraction, 
in the recovery of silver from photographic materials, in chemical manufacture, in the 
production of plastics, pigments and dyes, for the manufacture of methionine or other amino 
acids in the animal feed industry and as a pesticide/insecticide. However, by far the bulk of 
consumption of cyanide goes into methyl-methacrylate and into adiponitrile (a precursor of 
nylon) manufacture (3, 15, 16). In these industries and occupations, hydrogen cyanide can be 
produced by the contact of cyanide salts (sodium or potassium cyanide) with acids or acid 
salts, by the hydrolysis of other cyanide gases such as cyanogen chloride and can result from 
the combustion in fires at industrial sites, where cyanide is use (15, 17). 
Although rare, cyanide inhalation has already been used to commit suicide (18). 
 
• Ingestion 
Cyanide ingestion can occur as a suicide and homicide attempts and as an accidental 
ingestion (3). Suicide attempt has been described as the most common reason for cyanide 
ingestion (19). 
Although ingestion of cyanide is a quick and efficient method of suicide, it is not one of the 
leading suicidal causes of death (20). In a 10-year review of Kentucky Medical Examiner 
cases, among the 2864 cases of suicide analysed, only six resulted from cyanide poisoning 
(21). People who choose cyanide to commit suicide often have prompt access to the poison 
through their occupations. These include people involved in the industries stated above along 
with chemists, jewellers, laboratory scientists and technicians, among others (3, 5, 20, 22-26). 
Availability of a poison is one factor that determines the choice of a particular method of 
suicide. So it is not surprising that these occupational groups choose cyanide instead of others 
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poisons more commonly used (20). Throughout a 55-year period of study of the causes of 
death among female members of the American Chemical Society, among chemists who 
committed suicide, cyanide was the leading choice (39% of cases) (27). This study highlights 
the idea that the accessibility of cyanide in certain occupations may be a risk factor for this 
particular poisoning.  
As regards the jewellers, there are also some reports describing cases of cyanide poisoning 
among these workers. The Southeast Asian Hmong community has a tradition in jewellery, 
and some cases of suicidal and accidental ingestion of metal polish cleaner solutions 
containing cyanide salts, used to clean jewels and for shining coins, has been described in this 
community (28-30). There are also a few articles reporting the use of potassium cyanide 
containing solutions by Portuguese goldsmiths in suicidal attempts (25, 31). A review of the 
records of all patients admitted during a 20-year period at the emergency department of one 
hospital in the north of Portugal displayed six cases of acute cyanide poisoning involving 
these workers. These cases resulted from intentional ingestion of potassium cyanide salt, 
which was used in a jewellery polish cleaner solution. A case of accidental ingestion by a two 
year old infant was also reported (25). Cyanide salts are used in jewellery industry in certain 
regions of Portugal in order to perform a “gold stripping process”. It involves the use of a 
mixture of water and potassium cyanide (70%), which is boiled in a recipient, preferably of 
alloy enamel. The jewels are immersed in this mixture and then is add to it a small amount of 
hydrogen peroxide (90%), which reacts allowing the pickling of gold. This cleaning bath is 
reserved in order to recover residuum’s of gold lost in the process, since about 1% of gold is 
normally lost in this method (verbal communication from a local goldsmith). This procedure 
makes gold brighter in appearance and is used by almost every company in the gold 
manufacturing industry, especially in smaller and medium-sized facilities (25). Cyanide salts 
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are easily available to Portuguese goldsmiths in retail markets. Cyanide salts are normally 
sold as powder, in a plastic container closed with a lid.   
Historically, several murderers have employed cyanide to commit homicide and avoided 
detection for years, due in part to the fact that initial diagnosis is often missed in surreptitious 
cases by health care professionals (26). Owing to cyanide restricted availability to certain 
occupations, it is not surprising that some murderers belong to those professional groups (5, 
32).  
Cyanide ingestion can occur as an accident in some occupations, where it is use, or if 
someone, by mistake, ingest a product containing cyanide, thinking that is another substance 
(33, 34). Young children are a particular group of risk for accidental ingestion of substances 
containing poisons, placing these products in their mouths and/or ingest them as a means of 
exploration (35). In a retrospective review of cases of cyanide ingestion over seven years in 
the USA, 43 cases of children less than six years were reported, representing 10% of all 
paediatric cases. All of these 43 cases were unintentional (19). 
Nitriles are cyanogenic compounds which generate cyanide when burned or when 
metabolized in the body. They can release hydrogen cyanide during combustion, or after 
absorption through the skin or gastrointestinal tract, they are metabolized by the liver and 
subsequently release cyanide into the body. The onset of toxicity from metabolized nitrile 
compounds may be delayed from two to eight hours after initial exposure, so the failure to 
observe symptoms of poisoning in the initial minutes and hours after nitrile exposure should 
not be interpreted as the absence of toxicity. The most toxic of the nitrile compounds are 
acetonitrile, acrylonitrile, isobutyronitrile and methyl acrylonitrile and the most commonly 
encountered are acetonitrile and propionitrile. They are used as solvents, glue and nail polish 
removers, in the manufacturing of plastics and biotechnology processes (3, 4, 15, 35, 36). 
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Although acetonitrile is a common industrial solvent, it is a rare cause of poisoning, most 
often found in suicide attempts or due to accidental ingestion by young children (35-37). 
Laetrile is amygdalin, a cyanogenic glycoside that occurs in low concentrations in the seeds 
and fruit pits of Prunus species (e.g. cherry pits, bitter almonds and apricot pits) (4). It has 
been advocated as a treatment for various diseases, especially malignancies, but there has 
never been any scientific evidence of efficacy of amygdalin (38, 39). It is not approved for 
sale in the European Union, USA, Canada or Australia (38). Intravenous administration of 
amygdalin rarely causes toxicity as the substance is almost completely excreted unchanged in 
the urine. However, when ingested, it can release hydrogen cyanide by hydrolysis in the gut 
and then cause cyanide poisoning. This process occurs in the presence of heat, mineral acids, 
high doses of ascorbic acid and β-glucosidase (a component of the enzyme complex emulsin 
present in almonds and apricot kernels and produced by some gut bacteria) (39-41). The 
clinical effects of poisoning may become manifest in minutes to hours, because amygdalin 
does not undergo rapid conversion to cyanide (1, 40). Cyanide toxicity in this setting can 
occur as an accidental poisoning following ingestion of amygdalin with therapeutic intent, or 
as unintentional accident following laetrile ingestion, for example, by a child (38-40).   
Natural sources of cyanide include amygdalin, as stated previously, and similar cyanogenic 
compounds found in a wide variety of plants, like apple or pear seeds, peach or apricot 
kernels, lima beans, bitter almonds, cherry or plum kernels (42, 43). As described, cyanide is 
present in various alimentary sources. Ingestion of cyanogenic plants is relatively common 
but acute poisoning is rare since in small quantities these foods may not cause adverse 
effects. However, they can be lethal if ingested in large quantities, especially if the fruit 
kernels are grinding or chewing, which increases toxicity by releasing emulsin from 
lysosomes (44, 45). Apricot kernels, bitter almonds and choke cherries have been reported to 
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cause cyanide poisoning (43-48). Normally, signs and symptoms of cyanide toxicity are 
delayed after ingestion (43).  
 
• Dermal contact and parenteral administration 
Dermal exposure is rare and most reported cases of toxicity from dermal contact involved 
total body immersion in tanks of cyanide solution. However, there are reported cases where 
firemen experienced toxic symptoms high likely due to absorption of highly concentrated 
hydrogen cyanide gas through their intact skin (14, 49).  
Although a rarity, subcutaneous injection of cyanide has already been used in suicide and 
homicide attempts (50, 51). 
Sodium nitroprusside is an inorganic hypotensive agent used to lower blood pressure in 
hypertensive crisis and congestive heart failure and for producing controlled hypotension in 
order to reduce bleeding during surgery. It is 44% cyanide by molar weight and can be an 
iatrogenic source of this toxic. Sodium nitroprusside is rapidly broken down 
nonenzymatically to cyanogens after intravenous administration (4, 52, 53). Under normal 
conditions cyanide is detoxified by enzymatic conversion to thiocyanate through the action of 
rhodanese in the liver, which is then normally excreted by the kidney. Cyanide toxicity may 
be due to a defect in cyanide metabolism, impaired renal function which may not lead to 
excretion of thiocyanate at a sufficient rate, or to an accumulation of thiocyanate as a 
consequence of prolonged sodium nitroprusside infusion or administration at excessive doses 
(4, 54). 
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Clinical manifestations and laboratory findings 
All body systems are affected by cyanide poisoning since cells of all tissues rely on oxygen 
and ATP. Therefore, clinical manifestations of acute cyanide toxicity are a reflection of 
intracellular hypoxia. The heart and brain are particularly susceptible to this poisoning 
because of their requirement for a continuous and large supply of oxygen and ATP for 
normal function. Early symptoms reflect reflexive attempts of the cardiovascular, respiratory 
and neurologic systems to overcome tissue hypoxia. Late symptoms reflect these systems 
depression as tissues fail to compensate for their failure to use oxygen (1). Table 1 lists 
common symptoms of acute cyanide intoxication. 
Patients with acute cyanide poisoning have markedly elevated plasma lactate concentration, 
due to anaerobic metabolism. The normal range of plasma lactate concentration is 1 to 2 
mmol/L, but in cyanide poisoning lactate concentration often exceeds 8 mmol/L. This value 
was shown to be highly sensitive (94%) and moderately specific (70%) for a toxic blood 
cyanide concentration of ≥1 mg/L, in a sample of 11 patients exposed solely to cyanide (11). 
The process that produces this rise in plasma lactate concentration leads also to a high anion 
gap metabolic acidosis, defined by an arterial blood pH of less than 7.35 with a plasma 
bicarbonate concentration of less than 22 mmol/L. Since cyanide poisoned cells are unable to 
extract and use oxygen from arterial blood, venous blood is often nearly as oxygenated as 
arterial blood, this leading to the characteristic laboratory finding on blood gas analysis of 
elevated venous oxygen with reduced arteriovenous oxygen saturation difference (<10 
mmHg) in patients with acute cyanide poisoning (1, 4). Blood cyanide concentrations should 
be determined to confirm exposure to cyanide but the results of this test are generally not 
available in time to be useful in the initial diagnosis of poisoning. Moreover, blood cyanide 
concentrations can be misleading because of the rapid metabolism of cyanide, its instability 
in blood samples and the susceptibility of cyanide blood tests to interference (2). Blood 
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concentrations of cyanide greater than 0.5 mg/L are normally associated with cyanide 
toxicity, with levels approaching 3 mg/L or higher being potentially fatal if untreated (55).  
 
Diagnosis 
Since there is no blood cyanide test that can rapidly confirm poisoning, acute cyanide 
poisoning is presumptively diagnosed based on index of suspicion and clinical presentation. 
Rapid loss of consciousness and hemodynamic instability, in the presence of high anion gap 
metabolic acidosis with elevated plasma lactate (>8 mmol/L), particularly in someone in an 
occupation with potential exposure to cyanide, strongly suggest the possibility of acute 
cyanide poisoning (2).   
 
Treatment 
The first step in the initial management of acute cyanide poisoning is decontamination. 
Patients with suspected exposure to cyanide gas or fire smoke should be evacuated from the 
contaminated environment to an area with fresh air. Removal of contaminated clothing and 
washing of the skin with copious amounts of water should be done in cases of dermal 
exposure. In patients with suspected ingestion, emesis should not be induced. Activated 
charcoal may be administered if the victim is alert and the time is within one hour of the 
suspected ingestion, unless contraindicated. Early gastric lavage can also be done in the case 
of ingestion, if there is no contraindication (4, 56).  
Supportive care should occur simultaneously with decontamination. The principles of basic 
life support triad (airway, breathing and circulation) apply to treatment of acute cyanide 
poisoning. The administration of 100% oxygen by nonrebreather mask or endotracheal tube 
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is indicated. Although this will not correct the problem, since cyanide poisoning involves 
deficient oxygen utilization instead of deficient availability, 100% oxygen may enhance the 
effectiveness of antidotal therapy and is also essential to effective treatment of concurrent 
carbon monoxide exposure. Critically ill patients should be given advanced life support, 
including endotracheal intubation for comatose patients, vasopressors for cardiovascular 
collapse, sodium bicarbonate for metabolic acidosis and anticonvulsants for controlling 
seizures (2, 4, 56). 
After these measures are initiated, the key to treatment of acute cyanide poisoning is early 
administration of an antidote (4). The Cyanide Antidote Kit (CAK), 4-dimethylaminophenol 
(4-DMAP), dicobalt edetate and hydroxocobalamin are cyanide antidotes available in one or 
more countries around the world (57).  
The CAK consists of amyl nitrite, sodium nitrite and sodium thiosulfate, which are given 
together to enhance the onset and duration of action relative to those achievable with 
administration of any of the components alone (57). Amyl nitrite is given via inhalation over 
15 to 30 seconds while intravenous access is established. Then, sodium nitrite is administered 
intravenously over three to five minutes, followed by intravenous sodium thiosulfate 
administration during 30 minutes (4). Nitrite administration oxidizes ferrous (2
+
) iron to 
ferric (3
+
) iron in haemoglobin, causing the formation of methaemoglobin, which binds 
cyanide with greater affinity than cytochrome oxidase, releasing this enzyme for aerobic 
cellular respiration. Methaemoglobin serves as a temporary binding site for cyanide and 
thereby transiently reduces free (active) cyanide in the bloodstream (52). Sodium thiosulfate 
acts as a sulfhydryl donor that increases the rate of rhodanese-catalyzed transformation of 
cyanide to thiocyanate, which is renally excreted. The nitrites in the CAK may cause toxicity 
and pose potential risk to the patient. They can cause profound vasodilatation leading to 
hypotension, tachycardia and syncope. In addition, nitrite-induced methaemoglobinaemia 
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reduces the level of functional circulating haemoglobin, impairing oxygen transport to the 
cells. Therefore, it is desirable to monitor methaemoglobin levels, which should not exceed 
20%. Methaemoglobinaemia can be especially dangerous for victims of cyanide poisoning 
from smoke inhalation, who already have a reduction in the oxygen-carrying capacity of the 
blood, secondary to concomitant carbon monoxide poisoning. Therefore, the CAK is 
generally considered unsuitable for use in the prehospital setting in those suspected of having 
cyanide poisoning from inhalation of fire smoke (4, 56, 57).  
4-DMAP was first introduced in Germany as a cyanide antidote. It produces a profound 
methaemoglobinaemia, observed within a few minutes of its administration. Therefore, 
monitoring of methaemoglobin levels and availability of methylene blue for reversal of 
methaemoglobinaemia are recommended when 4-DMAP is used. It has the advantage that it 
may be administered intramuscularly and thus can be given by paramedical personnel. 4-
DMAP has been used in combination with other antidotes and as sole antidotal therapy. It is 
associated with severe side effects, including reticulocytosis, nephrotoxicity and haemolysis. 
Necrosis at the site of intramuscular injection has also been seen and there is concern that 
absorption will be poor in the acute stage of intoxication/collapse, where there is peripheral 
shutdown. Given its safety profile, 4-DMAP is also not well suited for prehospital empiric 
treatment of acute cyanide poisoning, especially in fire smoke-inhalation victims (16, 55, 57).    
Dicobalt edetate is currently used as a cyanide antidote in Europe. It is administered by fast 
(one minute) intravenous infusion and is very rapid in its effects, with the hypothesized 
mechanism of action being the chelation of cyanide to form cobalticyanide, which is much 
less toxic. But in the absence of cyanide to bind the free cobalt ions present in the solution 
containing the antidote, serious cobalt toxicity (cardiac and respiratory distress, abdominal 
pain and vomiting) can develop. Therefore, before giving dicobalt edetate one has to be 
certain that the victim is actually suffering from cyanide poisoning. Also, because it has been 
20 
 
suggested that glucose protects against cobalt toxicity, it is recommended that each injection 
of dicobalt edetate should be followed immediately by intravenous 50 mL of 50% glucose, 
even in patients with confirmed cyanide poisoning. Since this antidote is associated with 
significant toxicities, including vomiting, tachypnoea, chest pain, hypotension, ventricular 
arrhythmias, seizures, urticaria, facial, laryngeal or neck oedema and anaphylactic shock, it is 
not well suited for prehospital empiric treatment of acute cyanide poisoning and is 
recommended as a second-line antidote (15, 16, 55, 57).      
Hydroxocobalamin combines with cyanide to form the renally excreted, nontoxic 
cyanocobalamin. In the blood, cyanocobalamin releases cyanide at a rate slow enough to 
allow the enzyme rhodanese to detoxify the cyanide in the liver. Cyanide has a greater 
affinity for hydroxocobalamin than for the cytochrome oxidase, releasing the mitochondria 
for aerobic cellular respiration (4). A dose of 5 g hydroxocobalamin is administered by rapid 
intravenous infusion when cyanide poisoning is suspected and a second dose has to be 
repeated according to seriousness (55). This antidote has a favourable tolerability and safety 
profiles. It has the advantage of not interfering with tissue oxygenation, unlike other antidotes 
(57). A transient and apparent harmless reddish-brown discoloration of the skin, mucous 
membranes and urine, are the most common drug-related side effects of treatment with this 
antidote. It occurs due to the red colour of the medication and appears to resolve within two 
to three days of administration of the drug (4, 9). Because hydroxocobalamin has maximum 
absorption at wavelengths used in many colorimetric assays it can interfere with certain 
laboratory blood tests, such as those for bilirubin, creatinine, creatine kinase, glucose, 
phosphorus, magnesium, serum iron, serum aspartate aminotransferase, carboxyhaemoglobin, 
methaemoglobin and oxyhaemoglobin. Whether the values are falsely high or low is specific 
to the auto-analyzer and none appear to be of major clinical significance. Also, the impact on 
colorimetric laboratory values is transient (4, 9, 57, 58). Hydroxocobalamin has also been 
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associated with headache, erythema, exceptional allergic reactions, mild and transient 
hypertension accompanied by reflex bradycardia (7, 9, 59). This transient elevation in blood 
pressure appears to not pose significant risks in individuals without cyanide toxicity and may 
improve the hemodynamic status in patients with acute cyanide poisoning who are 
hypotensive (59). The safety and tolerability profiles of hydroxocobalamin, its rapid onset of 
action, the fact that it is not harmful when administered to non-poisoned patients and is safe 
in smoke-inhalation victims are reasons that explain why hydroxocobalamin has been 
recommended as an antidote of first choice. It is used empirically in the prehospital and 
hospital settings for cases in which acute cyanide poisoning from ingestion or inhalation is 
suspected but cannot be confirmed within the short time available for initiating effective 
intervention (55, 57-59). 
Sodium thiosulfate is synergistic with hydroxocobalamin and they are sometimes used 
together, especially in the critically ill patient. However, they should not be administered in 
the same intravenous line. It is believed that concurrent administration of sodium thiosulfate 
“recycles” the hydroxocobalamin binding and may reduce the amount of hydroxocobalamin 
required (9, 52, 58). Regarding cyanide toxicity induced by nitroprusside use, it may be 
prevented by sodium thiosulfate (infusion of 1 g to each 100 mg of sodium nitroprusside) or 
by hydroxocobalamin, while treatment of nitroprusside-induced acute cyanide poisoning with 
this later antidote is efficient (7, 55).   
 
Follow-up 
Discharge of the cyanide poisoned patient from hospital depends on the stabilization of 
symptoms and the resolution of acidosis and other metabolic abnormalities. Although most 
patients who survive cyanide toxicity will be free of complications, after discharge they 
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should be screening at regular intervals for delayed central nervous system effects (17). 
Patients may develop parkinsonism and other symptoms like dystonia, bradykinesia, slowed 
speech, personality changes, disordered memory and mathematical abilities (42, 56). These 
symptoms usually develop days to months after exposure to cyanide and are attributable 
either to the cerebral hypoxia from the acute intoxication process or to the direct toxic action 
of cyanide (56, 60, 61). Brain-imaging studies of patients with acute cyanide poisoning who 
manifested delayed central nervous systems effects show abnormalities in the basal ganglia, 
nigrostriatal pathways and the cerebral and cerebellar cortices (61, 62). Levodopa and 
dopamine agonists have been used in some of these cases, with apparent beneficial effects 
(61, 63). 
 
Conclusion 
The main causes of acute cyanide poisoning are inhalation of fire smoke, occupational or 
industrial accidents, suicide or homicide attempts, accidental ingestion and ingestion of 
cyanogenic substances, such as nitriles or cyanogenic plants. From these, smoke inhalation in 
a closed-space fire is the most common source in industrialised countries, and the possibility 
of cyanide intoxication in a fire victim should not be underestimated, especially if there is 
altered mental status or hemodynamic instability.  
Many occupations have access to cyanide, so the possibility of attempted suicide, accidental 
ingestion or occupational accident with this poison should be considered by emergency 
physicians in an individual from those professional groups that presents with rapid loss of 
consciousness and cardiovascular instability, in the presence of elevated plasma lactate (> 8 
mmol/L). 
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Hydroxocobalamin can be recommended as the first line antidote, in association with 
supportive treatment, in patients with suspected cyanide poisoning in the prehospital and 
hospital settings. 
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Table 
 
Table 1. Manifestations of acute cyanide poisoning (1, 2, 4, 35) 
System Manifestations 
Cardiovascular 
Early 
• Tachycardia 
• Transient increase in blood pressure 
Late 
• Hypotension 
• Bradycardia 
• ST-T wave changes 
• Supraventricular tachycardia 
• Atrioventricular block 
• Ventricular fibrillation 
• Asystole 
• Cardiovascular collapse 
Respiratory 
Early 
• Dyspnoea 
• Hyperventilation and tachypnoea 
Late 
• Absence of cyanosis  
• Hypoventilation 
• Apnoea 
• Respiratory arrest 
Central nervous 
Early 
• Anxiety 
• Confusion 
• Headache 
• Dizziness 
• Giddiness 
• Agitation 
• Disorientation 
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• Weakness 
• Malaise 
• Mydriasis 
Late 
• Lethargy  
• Stupor 
• Generalized seizures  
• Paralysis 
• Coma 
• Cerebral death 
Gastrointestinal 
• Nausea 
• Vomiting 
• Abdominal pain 
Dermatologic • Cherry-red discoloration of the skin 
Other 
• Bright-red retinal veins and arteries 
• Bitter-almond odor in some victims  
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syndrome, mechanism or be supportive of a new hypothesis? 
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Northbrook, IL, 60062, USA.  
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registration as a condition of publication for all studies involving clinical trials. Trial 
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